poisar

Stock

Palvella Therapeutics, Inc. PVLA

$142.97+0.09%

Overview

PVLA market data

Price History

PVLA price chart

Valuation & Profitability

Twelve Data
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$7.62
Diluted earnings per share over the trailing twelve months.
Beta
-0.19
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$34.57 – $161.38
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $2K · P/B 44.27 · P/S 50.06.

Company News

9 captured
Hasbro, Utz Brands, Park Aerospace And Other Big Stocks Moving Higher On TuesdayBenzinga · Jul 21, 2026, 2:37 PM
8-K filing — PALVELLA THERAPEUTICS, INC. (PVLA)SEC EDGAR · Jul 14, 2026, 8:48 PM
Palvella Therapeutics Submits First Module Of Rolling NDA To FDA Seeking Approval Of QTORIN 3.9% Rapamycin Anhydrous Gel For Treatment Of Microcystic Lymphatic MalformationsBenzinga · Jun 29, 2026, 11:40 AM
Palvella Therapeutics Announces FDA Rolling Review Of Its New Drug Application For Qtorin Rapamycin For The Treatment Of Microcystic Lymphatic MalformationsBenzinga · Jun 22, 2026, 11:40 AM
Palvella Therapeutics Receives U.S. Patent For Its Licensed QTORIN Pitavastatin Program For PorokeratosisBenzinga · May 27, 2026, 11:37 AM
Stephens & Co. Reiterates Overweight on Palvella Therapeutics, Maintains $220 Price TargetBenzinga · May 21, 2026, 3:30 PM
Palvella Therapeutics Presents New Clinical Data From Phase 3 SELVA And Phase 2 TOIVA Studies At ISSVA World Congress 2026Benzinga · May 20, 2026, 8:40 PM
Palvella Therapeutics Presents New Data From Phase 2 TOIVA Trial Of QTORIN Rapamycin In Patients With Cutaneous Venous Malformations At Annual Meeting Of SIDBenzinga · May 15, 2026, 11:40 AM
Palvella Therapeutics Receives Approval To Uplist To Nasdaq Global MarketBenzinga · May 13, 2026, 11:33 AM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock